Stela Gengrinovitch

4.3k total citations · 1 hit paper
11 papers, 3.5k citations indexed

About

Stela Gengrinovitch is a scholar working on Molecular Biology, Public Health, Environmental and Occupational Health and Hematology. According to data from OpenAlex, Stela Gengrinovitch has authored 11 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Public Health, Environmental and Occupational Health and 5 papers in Hematology. Recurrent topics in Stela Gengrinovitch's work include Acute Myeloid Leukemia Research (5 papers), Acute Lymphoblastic Leukemia research (5 papers) and Angiogenesis and VEGF in Cancer (4 papers). Stela Gengrinovitch is often cited by papers focused on Acute Myeloid Leukemia Research (5 papers), Acute Lymphoblastic Leukemia research (5 papers) and Angiogenesis and VEGF in Cancer (4 papers). Stela Gengrinovitch collaborates with scholars based in Israel, United States and Belgium. Stela Gengrinovitch's co-authors include Gera Neufeld, Tzafra Cohen, Ben-Zion Levi, Hela Gitay-Goren, Patricia Rockwell, Dina Ron, Bluma Berman, Guido David, Larry Witte and Theodore E. Maione and has published in prestigious journals such as Journal of Biological Chemistry, Blood and The FASEB Journal.

In The Last Decade

Stela Gengrinovitch

10 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Vascular endothelial growth factor (VEGF) and its receptors

1999 2.9k citations Gera Neufeld, Tzafra Cohen et al. The FASEB Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stela Gengrinovitch Israel	6	2.5k	826	698	370	331	11	3.5k
Saskia Pollefeyt France	9	2.8k 1.2×	829 1.0×	592 0.8×	494 1.3×	369 1.1×	9	3.9k
Bruce I. Terman United States	22	2.6k 1.1×	722 0.9×	684 1.0×	473 1.3×	204 0.6×	35	3.2k
Andrew C. Dudley United States	33	1.8k 0.7×	914 1.1×	662 0.9×	322 0.9×	201 0.6×	60	3.2k
Ronald L. Heimark United States	32	2.4k 1.0×	490 0.6×	449 0.6×	538 1.5×	483 1.5×	61	4.1k
Terri Davis-Smyth United States	9	3.3k 1.3×	1.2k 1.5×	980 1.4×	250 0.7×	407 1.2×	9	4.8k
Marya F. McCarty United States	29	2.0k 0.8×	869 1.1×	1.1k 1.6×	272 0.7×	146 0.4×	37	3.0k
Hitoshi Kitayama Japan	26	2.3k 0.9×	999 1.2×	901 1.3×	676 1.8×	271 0.8×	59	3.8k
Roberto F. Nicosia United States	35	2.2k 0.9×	707 0.9×	424 0.6×	336 0.9×	469 1.4×	64	3.3k
Paul Gutwein Germany	31	1.8k 0.7×	701 0.8×	816 1.2×	420 1.1×	180 0.5×	42	3.3k
Lidija Covic United States	37	1.9k 0.8×	1.2k 1.4×	689 1.0×	156 0.4×	317 1.0×	63	4.8k

Countries citing papers authored by Stela Gengrinovitch

Since Specialization

Citations

This map shows the geographic impact of Stela Gengrinovitch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stela Gengrinovitch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stela Gengrinovitch more than expected).

Fields of papers citing papers by Stela Gengrinovitch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stela Gengrinovitch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stela Gengrinovitch. The network helps show where Stela Gengrinovitch may publish in the future.

Co-authorship network of co-authors of Stela Gengrinovitch

This figure shows the co-authorship network connecting the top 25 collaborators of Stela Gengrinovitch. A scholar is included among the top collaborators of Stela Gengrinovitch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stela Gengrinovitch. Stela Gengrinovitch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Altman, Jessica K., Selina M. Luger, Olga Frankfurt, et al.. (2020). Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation. Blood. 136(Supplement 1). 9–10.

Zuckerman, Tsila, Ron Ram, Luiza Akria, et al.. (2019). BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study. Blood Advances. 3(22). 3740–3749. 10 indexed citations

Tessler, Shoshi, Inbal Mishalian, Stela Gengrinovitch, et al.. (2018). BST-236, a Novel Cytarabine Prodrug, Is Safer and As Effective As Cytarabine in In Vivo Leukemia Models. Blood. 132(Supplement 1). 1451–1451. 3 indexed citations

Zuckerman, Tsila, Ron Ram, Maya Koren‐Michowitz, et al.. (2017). BST-236, a Novel Cytarabine Pro-Drug, Enables Safe and Effective Administration of High Dose Cytarabine to Older or Unfit Patients with Acute Leukemia. Results of a Phase I/II Study. Blood. 130(Suppl_1). 893–893. 1 indexed citations

Zuckerman, Tsila, Stela Gengrinovitch, Ron Hoffman, et al.. (2016). Astarabine, a Novel Leukemia-Targeted Cytarabine Composition Allows, for the First Time, the Delivery of High Cytarabine Doses for Older or Unfit Patients with Acute Leukemia. Results of an Ongoing Phase I/IIa Study. Blood. 128(22). 1650–1650. 2 indexed citations

Gengrinovitch, Stela, et al.. (2015). Astarabine, a Cytarabine Pro-Drug, Is Safe and Efficacious in the Treatment of Leukemia - Results of Animal Studies. Blood. 126(23). 2545–2545. 1 indexed citations

Vadasz, Zehava, Ofra Kessler, Gal Akiri, et al.. (2005). Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2. Journal of Hepatology. 43(3). 499–507. 150 indexed citations

Neufeld, Gera, et al.. (1999). Vascular endothelial growth factor (VEGF) and its receptors. The FASEB Journal. 13(1). 9–22. 2890 indexed citations breakdown →

Gengrinovitch, Stela, Bluma Berman, Guido David, et al.. (1999). Glypican-1 Is a VEGF165 Binding Proteoglycan That Acts as an Extracellular Chaperone for VEGF165. Journal of Biological Chemistry. 274(16). 10816–10822. 157 indexed citations

10.

Gitay-Goren, Hela, Tzafra Cohen, Shay Söker, et al.. (1996). Selective Binding of VEGF121 to One of the Three Vascular Endothelial Growth Factor Receptors of Vascular Endothelial Cells. Journal of Biological Chemistry. 271(10). 5519–5523. 160 indexed citations

11.

Gengrinovitch, Stela, Sheryl M. Greenberg, Tzafra Cohen, et al.. (1995). Platelet Factor-4 Inhibits the Mitogenic Activity of VEGF121 and VEGF165 Using Several Concurrent Mechanisms. Journal of Biological Chemistry. 270(25). 15059–15065. 163 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact